A Germany-based mid-sized pharma company actively engaged in the late-stage development of a therapy for Primary Immunodeficiency (PID) and, with a strong marketing and drug commercialization presence in Europe, sought to assess the launch readiness of competitors to position its product…
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.